Prostate Cancer Market

Oct 11, 2024

Prostate cancer is one of the most common cancers among men, affecting about 1 in 8 men in the United States at some point in their lives. According to estimates from DelveInsight, there were nearly 8.2 million total cases of prostate cancer in the 7MM in 2023, although this number does not indicate how many of the...

Sep 25, 2024

Every September, the spotlight turns to prostate cancer. Prostate cancer stands as one of the most prevalent cancers among men, affecting approximately 1 in 8 men in the United States during their lifetime. With nearly 288,000 new cases diagnosed each year, men must prioritize regular screenings and early detection...

Feb 24, 2023

The ASCO Genitourinary (GU) Cancers Symposium, which ended on February 18, 2023, was a three-day scientific and educational meeting designed to provide attendees with in-depth, multidisciplinary analysis of the timely topics in the study, diagnosis, and treatment of GU malignancies. DelveInsight has compiled the sy...

Jul 19, 2022

Byondis Files its HER2-Targeting Antibody-Drug Conjugate (ADC) Trastuzumab Duocarmazine in the US and Europe Byondis has filed for clearance of its HER2-targeting antibody-drug conjugate (ADC) trastuzumab duocarmazine in the United States and Europe, setting up a battle with heavyweight competitors Roche and Ast...

Mar 18, 2022

Prostate cancer is the third most frequent cancer in the United States and the fourth most common worldwide. 1 in every 9 males in the United States will be diagnosed with Prostate Cancer at some time in their life. According to the American Cancer Society, Prostate Cancer is the second largest cause of cancer mort...

Feb 21, 2022

Delveinsight brings you the comparative analysis on Positive Phase III trial results of PARP inhibitors, Zejula (Niraparib) and Lynparza (Olaparib) in metastatic CRPC patient population. PARP inhibitors are one of the most promising therapeutic classes in the phase III pipeline, based on the demonstrated effecti...

Jun 05, 2020

Prostate Cancer Market Size is Expected to Increase with a CAGR of 8.1% in the 7MM for the study period of 2017-30 owing to rich Pipeline, Increasing Awareness and Better Treatment Options. A malignancy of prostate glands, Prostate Cancer, develops slowly and remains confined to prostate glands, however, can inv...